MaxCyte Net Income

The latest net income for MXCT is $-36M as of June 2026. That compares with $-45M in the prior-year period — up 20.4% year over year. That is below the Materials sector average of $18B. Investors often review this figure alongside MaxCyte's historical trend and sector peers before judging valuation or financial health.

Over the past year, MXCT's net income moved from $-45M to $-36M — a 20.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in MaxCyte's operating scale or balance-sheet position.

Against Materials companies, MXCT currently prints $-36M for net income, while the sector average sits near $18B. That is roughly 100.2% below the sector mean. Large gaps often invite a closer look at MaxCyte's growth, margins, and balance sheet.

A net income figure of $-36M for MXCT is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Materials average is about $18B. Explore the charts below for those layers of context.

After noting MXCT's net income ($-36M), review year-over-year change from $-45M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.